Singapore's biomedical sciences landscape
- PDF / 185,014 Bytes
- 8 Pages / 595.276 x 765.354 pts Page_size
- 52 Downloads / 181 Views
Keat-Chuan Yeoh was appointed Executive Director of the Economic Development Board’s Biomedical Sciences Cluster on 1st March, 2007. Biomedical Sciences covers Pharmaceuticals, Biotechnology, Medical Technology and Healthcare Services. Keat Chuan is a Glaxo-EDB scholar who graduated with a Master of Engineering (Chemical Engineering), from Imperial College of Science, Technology & Medicine, University of London. Keat Chuan also attended Stanford University’s Graduate School of Business and graduated as a Sloan Fellow in July 2004. He spent seven years based in the US as Centre Director (Washington, DC) and Regional Director (Eastern US) of the Economic Development Board’s Global Operations.
Abstract Singapore’s vision is to be the Biopolis of Asia, a leading international biomedical sciences cluster advancing human health, through the pursuit of excellence in research and development, manufacturing and healthcare delivery. To achieve this, Singapore has built up world-class capabilities across the entire value chain from drug discovery, development and clinical research, to manufacturing and healthcare delivery. In the year 2000, Singapore’s Biomedical Sciences (BMS) initiative was launched to establish a focused effort on the development of this sector as the fourth pillar of Singapore’s industry cluster, alongside electronics, chemicals and engineering. The BMS initiative covers the Pharmaceutical, Biotechnology, Medical Engineering and Technology and Healthcare Services industries. An integrated strategy was adopted for the development of the BMS sector, focusing on Human Capital, Intellectual Capital and Industrial Capital, or 3 Cs in short. The first phase of the BMS initiative (2000–2005) put in place key building blocks by establishing core capabilities in biomedical research, and introducing important human capital and industrial capital development initiatives. For the next phase (2006–2010), we will build on this foundation and strengthen our capabilities in translational and clinical research to bring discoveries from the bench to the bedside and the marketplace, and ultimately improve human healthcare.
Journal of Commercial Biotechnology (2008) 14, 141–148. doi:10.1057/palgrave.jcb.3050083; published online 25 December 2007 Keywords: Singapore, biotechnology, opportunities, Biomedical Sciences
INTRODUCTION Singapore offers unlimited opportunities for Biomedical Sciences (BMS) companies. Strong government support and a pro-business environment have attracted industry leaders such as Abbott, Aventis, Affymetrix, Baxter, Becton-Dickinson, Eli Lilly, Genentech,
Correspondence: Keat-Chuan Yeoh, 20 Biopolis Way, Centros, #09-01, Singapore 138668, Singapore. Tel: + 65 6395 7711 Fax: + 65 6395 7798 E-mail: [email protected]
© 2008 PALGRAVE MACMILLAN LTD 1462-8732 $30.00
GlaxoSmithKline, Lonza, Merck & Co, Novartis, Pfizer, Schering-Plough, Siemens and Wyeth to Singapore for manufacturing and R&D activities. The three groups that are involved in Singapore’s BMS initiative are the Biomedical Sciences
Data Loading...
